Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial (Q84747835)

From Wikidata

Jump to navigation Jump to search

scientific article published on 09 August 2011

Language	Label	Description	Also known as
English	Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial	scientific article published on 09 August 2011

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21835220%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21835220%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

placebo-controlled trial

1 reference

based on heuristic

inferred from title

author name string

John J Treanor

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21835220%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Hana El Sahly

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21835220%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

James King

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21835220%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Irene Graham

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21835220%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Ruvim Izikson

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21835220%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Robert Kohberger

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21835220%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Peter Patriarca

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21835220%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Manon Cox

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21835220%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

publication date

9 August 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21835220%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21835220%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

29

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21835220%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

44

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21835220%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

7733-7739

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21835220%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.128

7 January 2021

Influenza A (H1N1) vaccine efficacy in animal models is influenced by two amino acid substitutions in the hemagglutinin molecule

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.128

7 January 2021

Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.128

7 January 2021

Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.128

7 January 2021

Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.128

7 January 2021

Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.128

7 January 2021

Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.128

7 January 2021

Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.128

7 January 2021

Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.128

7 January 2021

Symptomatic pericarditis after influenza vaccination: report of two cases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.128

7 January 2021

Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.128

7 January 2021

Antibody response to influenza vaccination in the elderly: a quantitative review

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.128

7 January 2021

Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.128

7 January 2021

Influence of prior influenza vaccination on antibody and B-cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.128

7 January 2021

Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.128

7 January 2021

Comparative efficacy of inactivated and live attenuated influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.128

7 January 2021

Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.128

7 January 2021

Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.128

7 January 2021

Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.128

7 January 2021

Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.128

7 January 2021

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.128

7 January 2021

Identifiers

10.1016/J.VACCINE.2011.07.128

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21835220%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21835220%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84747835&oldid=1753299037"